Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada
Executive Summary
A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.
You may also be interested in...
Sanofi Creates Consumer Unit With Eye To Expansion
Former Bayer executive Alan Main tapped to lead Consumer HealthCare global business unit, which Sanofi will consider expanding through acquisitions after integrating OTC brands added in a recent swap with Boehringer Ingelheim.
Sanofi Creates Consumer Unit With Eye To Expansion
Former Bayer executive Alan Main tapped to lead Consumer HealthCare global business unit, which Sanofi will consider expanding through acquisitions after integrating OTC brands added in a recent swap with Boehringer Ingelheim.
Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.